Latent hazard in PC and BPH patients referred to antiandrogens:PC aggressiveness and NE differentiation

Antiandrogen treatment of BPH often involves finasteride therapy yielding intraprostatic DHT deficiency. We reported that prolonged antiandrogen therapy may provoke the acquisition of neuroendocrine (NE) activity within the prostate. NE differentiation is a risk factor for the development of an aggressive prostate cancer. This study was undertaken to elucidate the cancer development hazard in BPH patients (pts) treated with finasteride.